Gossamer Bio (GOSS) Revenue & Revenue Breakdown
Gossamer Bio Revenue Highlights
Latest Revenue (Q)
$95.84M
Gossamer Bio Revenue by Period
Gossamer Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Gossamer Bio generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Gossamer Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $95.84M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $6.78M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Gossamer Bio generated $95.84M in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Gossamer Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| ALEC | Alector | $97.06M | $15.89M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| GOSS | Gossamer Bio | - | $95.84M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| REPL | Replimune Group | - | - |
| PASG | Passage Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| NVCT | Nuvectis Pharma | - | - |
| AKRO | Akero Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
GOSS Revenue FAQ
What is Gossamer Bio’s yearly revenue?
Gossamer Bio's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. GOSS's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Gossamer Bio’s quarterly revenue?
Gossamer Bio's quarterly revenue for Q2 2024 was $95.84M, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). GOSS's quarterly revenue for Q4 2023 was $6.78M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Gossamer Bio’s revenue growth rate?
Gossamer Bio's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.